$IOVA SETTING UP FOR STRONG MOVE TOMORROW, FDA REVIEW

******CONTINUATION LOOKS ON THE CARDS TOMORROW, STRONG GAINS THE AFTER HOURS ONCE AGAIN ON GOOV VOLUME. CURRENTLY ON RESISTANCE AT $18 A BREAK COULD BE VERY REWARDING.
***********NEWS FLOW*********
The FDA designates Iovance Biotherapeutics' (NASDAQ:IOVA) LN-145 a Breakthrough Therapy for the treatment of recurrent, metastatic, or persistent cervical cancer that has progressed on or after chemotherapy.
Breakthrough Therapy status provides for more intensive guidance from the FDA on development, the involvement of more senior agency personnel and a rolling review of the marketing application.